Insider Selling: Progyny (NASDAQ:PGNY) Director Sells $321,310.00 in Stock

Progyny, Inc. (NASDAQ:PGNY) Director Kevin Gordon sold 11,500 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $27.94, for a total transaction of $321,310.00. Following the completion of the sale, the director owned 6,792 shares of the company’s stock, valued at approximately $189,768.48. The trade was a 62.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Progyny Trading Down 1.4%

NASDAQ PGNY opened at $27.38 on Thursday. The business’s 50 day moving average is $28.52 and its two-hundred day moving average is $24.16. Progyny, Inc. has a 12-month low of $16.10 and a 12-month high of $33.06. The stock has a market capitalization of $2.10 billion, a price-to-earnings ratio of 29.76, a PEG ratio of 1.92 and a beta of 0.99.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The business had revenue of $350.51 million during the quarter, compared to analysts’ expectations of $349.05 million. During the same period last year, the firm earned $0.19 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Equities analysts forecast that Progyny, Inc. will post 1.25 earnings per share for the current fiscal year.

Progyny announced that its Board of Directors has approved a stock repurchase program on Tuesday, May 26th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 10.3% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Public Employees Retirement System of Ohio acquired a new stake in Progyny in the 2nd quarter valued at about $29,000. Nykredit A S purchased a new stake in shares of Progyny in the second quarter valued at about $38,000. Hantz Financial Services Inc. grew its position in shares of Progyny by 79.4% in the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after purchasing an additional 742 shares during the last quarter. IFP Advisors Inc increased its stake in shares of Progyny by 376.0% during the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock worth $57,000 after purchasing an additional 1,549 shares in the last quarter. Finally, Toth Financial Advisory Corp purchased a new position in shares of Progyny during the 2nd quarter worth approximately $65,000. Institutional investors and hedge funds own 94.93% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PGNY. Wells Fargo & Company began coverage on shares of Progyny in a report on Thursday, August 20th. They issued an “overweight” rating and a $37.00 price target for the company. Weiss Ratings downgraded shares of Progyny from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, August 31st. Zacks Research upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 8th. Jefferies Financial Group set a $33.00 target price on shares of Progyny in a report on Tuesday, September 8th. Finally, Citigroup reiterated an “outperform” rating on shares of Progyny in a research report on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Progyny presently has a consensus rating of “Moderate Buy” and an average price target of $34.36.

About Progyny

Progyny, Inc is a benefits management company that provides fertility and family-building solutions to employers and their employees. Its platform is designed to support individuals and couples pursuing fertility treatment, including in vitro fertilization, egg freezing, donor services, gestational surrogacy and adoption.

The company’s services combine access to a network of fertility specialists with personalized guidance, care coordination and treatment support. Progyny also offers pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.